MedPath

To study the effect of Unani formulation of paste in acne vulgaris.

Phase 2
Conditions
Health Condition 1: L700- Acne vulgaris
Registration Number
CTRI/2024/02/062474
Lead Sponsor
Central Council for Research in Unani Medicine New Delhi
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Patients of age group 15-60 years.

2. Clinically diagnosed patients of Buthur Labaniyya.

3. Patients Irrespective of the gender.

4. Patients with mild to moderate form of acne.

5. Patients who will agree to sign the informed consent form & follow the protocol.

Exclusion Criteria

1. Patients with severe form of acne.

2. Diagnosed patients of PCOD.

3. Patients having local wound and infection on face.

4. Pregnant and lactating women.

5. Patients with systemic diseases like DM, CKD, Chronic liver diseases,and history of Thyroid diseases or malignancies.

6. Patients on corticosteroid therapy, anti-convulsant therapy or taking OCP.

7. Patients suffering from other concomitant diseases like acne rosacea, acne fulminans, acne necrotica, psoriasis, eczema etc.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.Change in inflammatory lesions (Papules and Pustules) and non-inflammatory lesions (Open and Closed Comedones) (GAGS-Global Acne Grading System). <br/ ><br>2) Change in the inflammatory (Papules and Pustules) lesions based on photographs of lesions. <br/ ><br>3) Change in the quality of life of subjects based on the Dermatology Life Quality Index (DLQI).Timepoint: 0th day, 7th day, 14th day, 21st day, 28th day, 35th day, 42nd day
Secondary Outcome Measures
NameTimeMethod
1) Effect on redness based on Clinical Erythema Assessment (CEA). <br/ ><br>2) Effect on eruptions based on Simple Grading System by Indian Authors.Timepoint: 0th day, 7th day, 14th day, 21st day, 28th day, 35th day, 42nd day.
© Copyright 2025. All Rights Reserved by MedPath